Manabu Kurokawa conducts research primarily focused on the molecular mechanisms of cell death and metabolic adaptation in oncology. Publicly indexed outputs suggest a significant emphasis on evading apoptosis in cancer, a topic explored in a highly cited 2013 review that characterizes how malignant cells bypass programmed cell death. His work frequently investigates the intersection of signaling pathways, such as the regulatory interplay between caspases and kinases during cellular distress. More recent senior-authored research has shifted toward metabolic signaling, specifically identifying CD36-mediated metabolic rewiring as a key driver of resistance to HER2-targeted therapies in breast cancer. These contributions highlight a sustained inquiry into how biochemical shifts allow cancer cells to survive therapeutic intervention. Beyond oncology, earlier research contributions involve significant work in reproductive biology and calcium signaling. This includes participation in studies identifying the